Viridian Therapeutics (VRDN) Q2 2026 earnings summary

Executive summary

• FDA approved Lumvoa (veligrotug-vvze) for thyroid eye disease (TED) in June 2026, marking the first commercial product launch in the U.S. and the first TED therapy with both active and chronic data in its label, following strong phase 3 results and priority review.

• Commercial launch infrastructure established, with strong early physician engagement and payer adoption efforts.

• Elegrobart, a subcutaneous autoinjector for TED, met primary and secondary endpoints in pivotal phase 3 trials for both active and chronic TED, supporting a planned BLA submission in Q1 2027.

• Pipeline includes FcRn inhibitors (VRDN-006, VRDN-008) and a TSHR inhibitor for autoimmune diseases, with key IND and clinical milestones expected in 2026.

• Secured up to $1.3B in capital since 2025, with $981.5M cash as of June 30, 2026, supporting business plans through profitability.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $981.5 million as of June 30, 2026.

• Net loss for Q2 2026 was $127.1 million, compared to $100.7 million in Q2 2025; six-month net loss was $232.0 million.

• Revenue for Q2 2026 was $0.3 million, primarily from license and collaboration agreements.

• Operating expenses increased to $126.6 million in Q2 2026, driven by higher SG&A and R&D costs.

• Access to up to ~$1.3B in capital since 2025 through licensing, royalty, equity, and debt deals.

Outlook and guidance

• Anticipated BLA submission for elegrobart in Q1 2027 for both Q4W and Q8W dosing regimens.

• IND submission for anti-TSHR candidate expected in Q4 2026; VRDN-008 healthy volunteer data expected 2H 2026.

• Current cash and anticipated revenues from Lumvoa and elegrobart (if approved) expected to fund operations through profitability.

• Expects continued investment in R&D and commercial infrastructure.

• Plans to expand leadership in TED and autoimmune diseases, with continued pipeline development.